Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2883431 | 0.90 | HRH3 (0.72) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2881594 | 0.87 | HRH3 (0.73) | HRH3SLC6A4SLC6A2SLC6A3KDM4E | |
| SCHEMBL2889549 | 0.84 | SLC6A4 (1.00) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2887205 | 0.83 | HRH3 (0.73) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2887258 | 0.77 | SLC6A4 (0.67) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2880852 | 0.75 | SLC6A4 (1.00) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2887425 | 0.74 | SLC6A4 (1.00) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2887495 | 0.74 | SLC6A4 (1.00) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2888661 | 0.74 | SLC6A4 (1.00) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2881601 | 0.72 | SLC6A4 (1.00) | HRH3SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767666-B2 | Butyl and butynyl benzyl amine compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-03 | — | — | US | disclosed |
| US-20080004258-A1 | BUTYL AND BUTYNYL BENZYL AMINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004258-A1 | BUTYL AND BUTYNYL BENZYL AMINE COMPOUNDS | HRH3, HNMT, HRH4 | HRH3 1/4885SLC6A4 10/4885SLC6A2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.